VANGUARD GROUP INC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$38,400,641
-26.0%
2,071,232
-55.9%
0.00%0.0%
Q2 2023$51,913,616
-1.8%
4,693,817
+19.3%
0.00%0.0%
Q1 2023$52,859,392
+17.5%
3,935,919
+8.2%
0.00%0.0%
Q4 2022$45,001,256
+19.2%
3,637,935
+34.4%
0.00%0.0%
Q3 2022$37,755,000
+9.0%
2,706,414
+7.9%
0.00%0.0%
Q2 2022$34,652,000
-10.9%
2,509,159
+5.0%
0.00%0.0%
Q1 2022$38,873,000
+21.0%
2,389,249
+21.2%
0.00%0.0%
Q4 2021$32,120,000
-23.6%
1,971,759
-30.3%
0.00%0.0%
Q3 2021$42,030,000
-37.6%
2,830,263
-16.1%
0.00%
-50.0%
Q2 2021$67,363,000
-11.5%
3,373,212
+2.3%
0.00%0.0%
Q1 2021$76,074,000
+8.9%
3,296,117
+16.5%
0.00%0.0%
Q4 2020$69,875,000
-38.5%
2,828,955
+3.3%
0.00%
-50.0%
Q3 2020$113,593,000
-4.6%
2,739,825
+10.2%
0.00%0.0%
Q2 2020$119,067,000
-19.4%
2,485,217
+6.0%
0.00%
-33.3%
Q1 2020$147,639,000
-48.1%
2,344,972
+2.1%
0.01%
-40.0%
Q4 2019$284,574,000
+86.5%
2,296,438
-0.1%
0.01%
+66.7%
Q3 2019$152,620,000
-17.9%
2,299,880
-1.6%
0.01%
-14.3%
Q2 2019$186,005,000
-18.6%
2,337,622
+14.5%
0.01%
-22.2%
Q1 2019$228,413,000
+12.9%
2,041,948
+1.8%
0.01%0.0%
Q4 2018$202,247,000
-18.0%
2,006,622
+2.7%
0.01%
-10.0%
Q3 2018$246,772,000
+54.9%
1,952,931
+2.8%
0.01%
+42.9%
Q2 2018$159,336,000
+79.0%
1,898,893
+31.2%
0.01%
+75.0%
Q1 2018$89,029,000
+8.4%
1,447,135
+2.9%
0.00%0.0%
Q4 2017$82,123,000
+2.2%
1,405,731
+1.6%
0.00%0.0%
Q3 2017$80,330,000
-50.0%
1,384,056
+4.2%
0.00%
-50.0%
Q2 2017$160,797,000
+11.9%
1,328,133
+4.5%
0.01%
+14.3%
Q1 2017$143,749,000
+9.0%
1,270,984
+4.7%
0.01%0.0%
Q4 2016$131,905,000
-32.0%
1,214,032
+3.0%
0.01%
-36.4%
Q3 2016$194,065,000
+18.3%
1,179,083
+2.6%
0.01%
+10.0%
Q2 2016$164,047,000
+15.6%
1,149,749
+4.1%
0.01%
+11.1%
Q1 2016$141,897,000
-12.8%
1,104,508
+1.4%
0.01%
-18.2%
Q4 2015$162,740,000
-53.3%
1,089,655
-48.2%
0.01%
-15.4%
Q3 2015$348,824,000
+44.3%
2,103,126
+110.1%
0.01%
-18.8%
Q2 2015$241,674,000
-10.2%
1,001,214
+4.9%
0.02%
-11.1%
Q1 2015$269,209,000
+129.0%
954,574
+26.7%
0.02%
+125.0%
Q4 2014$117,573,000
-31.8%
753,676
+3.5%
0.01%
-38.5%
Q3 2014$172,367,000
+12.1%
728,242
+12.0%
0.01%
+8.3%
Q2 2014$153,826,000
-19.7%
650,073
+11.9%
0.01%
-25.0%
Q1 2014$191,509,000
+960.9%
580,699
+119.6%
0.02%
+700.0%
Q4 2013$18,052,000
+36.7%
264,381
+38.2%
0.00%
+100.0%
Q3 2013$13,202,000
+59.3%
191,261
+3.5%
0.00%0.0%
Q2 2013$8,290,000184,8660.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders